Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Brantingham

Podiatrist, Foot & Ankle Surgery Brookings, OR Doctor of Podiatric Medicine

NPI 1689195505 CMS profile 3133106

500 5Th St, Brookings, OR 97415

Open in the dashboard

General payments

$9,942

100 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Brantingham of Brookings, OR is reported in the CMS Open Payments database as having received $9,942 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,271 11
2024 General $236 11
2023 General $2,108 18
2022 General $1,638 13
2021 General $59 2
2020 General $488 13
2019 General $4,141 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Brantingham
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Steven Brantingham were reported at $1,271. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Steven Brantingham Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $4,141 $389 $118–$1,406 $163
2020 $488 $191 $62–$691 $114
2021 $59 $329 $104–$1,341 $132
2022 $1,638 $419 $125–$1,611 $149
2023 $2,108 $377 $128–$1,164 $160
2024 $236 $394 $134–$1,168 $164
2025 $1,271 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Treace Medical Concepts, Inc. $4,606 21 payments
  2. Stryker Corporation $4,032 30 payments
  3. Organogenesis Inc. $805 35 payments
  4. Wright Medical Technology, Inc. $276 6 payments
  5. Integra LifeSciences Corporation $112 3 payments
  6. Melinta Therapeutics, Inc. $51 2 payments
  7. Flexion Therapeutics, Inc. $26 1 payment
  8. Steelhead Surgical Inc $17 1 payment
  9. Bioventus LLC $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $5,531 15 payments
  2. Food and Beverage $3,697 84 payments
  3. Grant $714 1 payment
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM $3,443 14 payments
  2. None $2,476 7 payments
  3. STAR $921 13 payments
  4. LAPIPLASTY SYSTEM 1 $816 2 payments
  5. HOFFMANN $630 8 payments
  6. Puraply $361 19 payments
  7. ANCHORAGE $281 2 payments
  8. LAPIPLASTY $275 2 payments
  9. VARIAX $268 3 payments
  10. AXSOS $175 2 payments
  11. Other $1,571 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

187

Median for Podiatry: 160

Drug cost

$1,812

Median for Podiatry: $2,368

Branded share of claims

55.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 55 $615
Ciclopirox Generic 14 $415
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 36 $356
Cephalexin Generic 16 $164
Gabapentin Generic 12 $81
Celecoxib Generic 11 $71
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $58
Meloxicam Generic 31 $53

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record